versus 30-day were associated with a signifi cant higher MPRs and persistency. Efforts to increase medication adherence should be continued steadily along the course of therapy as a medication adherence with chronic medications continues to decrease over time.
PIH30

PATTERNS OF UTILIZATION AND DISCONTINUATION OF MEDICATION IN A RETIREE POPULATION
Visaria J J Ohio State University, Columbus, OH, USA OBJECTIVES: To describe the patterns of medication discontinuation in a retiree population. Premature discontinuation of medications adversely affects patients' outcomes and may require use of additional health care resources. METHODS: The study included pharmacy claims from a retirement system for the period January 2000-September 2005. The unit of analysis was the course of drug therapy (CDT), representing a unique combination of a patient and a drug product (i.e. generic name, formulation and strength). CDTs initiated between August 1, 2000 and July 31, 2001 and discontinued before March 1, 2005 were included in the analysis. Days in therapy for each CDT were calculated as the difference between the date of the fi rst and last prescription of the CDT. RESULTS: The study included 1.1 million CDTs representing 5.9 million claims. 37.0% of CDTs were discontinued with less than a month in therapy, 50.0% with less than 6 months, and 76.0% within one year. Maintenance therapy comprised 740,788 CDTs (70.30%) of which 27.0% had a single claim. Maintenance therapies had the following cumulative utilization patterns: 36.7% CDTs discontinued in less than 3 months of therapy, 45.0% in less than 6 months, 74.7% within one year, and 87.2% within two years. 21.6% of non-maintenance CDTs were continued for more than a year and 11.8% for more than 2 years. CONCLUSIONS: Premature discontinuation of therapy intended for long-term use is highly prevalent with more than one-fourth of all maintenance therapies discontinued at the fi rst prescription, and nearly three-fourths discontinued within the fi st year of therapy. In the other hand, over one-fi fth of non-maintenance therapies were used for over a year. The assessment of compliance using claims data should account for discontinuation of therapy prior to the potential manifestation of positive patient outcomes and for the short-term usage of maintenance therapies and prolonged use of non-maintenance therapies.
PIH31 ASSESSING THE VALUE OF LESS FREQUENT MEDICATION DOSING ON ADHERENCE AND OUTCOMES
Veenstra DL 1 , Alfonso R 1 , Best JH 2 , Bruhn D 3 , Garrison LP 1 1 University of Washington, Seattle, WA, USA, 2 Amylin Pharmaceuticals, Inc., San Diego, CA, USA, 3 Eli Lilly and Company, Indianapolis, IN, USA OBJECTIVES: To systematically evaluate studies assessing the outcomes and economic value of decreased medication dosing frequency. METHODS: We searched the literature from 1998 to 2008 using the MEDLINE database for articles that evaluated the cost-effectiveness of dosing frequency changes and adherence. Only non-English articles were initially excluded; from the identifi ed citations, all abstracts were reviewed; those lacking a clear link between dosing frequency changes, adherence, and costs or cost-effectiveness analysis (CEA) were excluded. The selected articles were thoroughly reviewed and summarized. RESULTS: A total of 168 citations were identifi ed: after exclusions by reviewing the abstracts, 21 were selected and reviewed-18 original studies and three systematic reviews. The articles encompassed several chronic pathologies, e.g., osteoporosis (seven) and hepatitis C (two). Seven of the ten economic studies utilized decision modeling frameworks (usually one-year horizon), where the effect of dosing frequency changes on adherence was not the primary outcome. In most cases, assumptions on adherence changes were used as part of the sensitivity analysis, but lacked support from strong evidence. Only two randomized clinical trials where adherence was not the primary outcome reported the effect of dosing changes, but focused, as did cross-sectional surveys, on patient preferences instead of costeffectiveness. Observational studies and retrospective claims database reviews used different measures, defi nitions, and methodologies, making it diffi cult to summarize their results. Overall, the studies suggested that less frequent dosing leads to improved outcomes, although direct evidence of economic benefi t was often lacking. CONCLU-SIONS: Due to the lack of direct evidence, head-to-head direct comparisons of dosing regimens and long-term prospective studies are ideally needed to evaluate the costeffectiveness of less frequent dosing that may improve outcomes through improved adherence or improved pharmacokinetic/pharmacodynamic effects.
PIH32 THE BRAZILIAN PORTUGUESE VALIDATION OF THE PROLAPSE -QUALITY OF LIFE QUESTIONNAIRE -P-QOL
Scarlato A 1 , Fonseca ESM 2 , Fonseca MCM 2 , Muranaka AH 3 , Sartori MGF 2 , Girão MJBC 2 , Castro RA 2 1 Federal University of São Paulo, São Paulo, Brazil, 2 UNIFESP -Federal University of Sao Paulo, Sao Paulo, Sao Paulo, Brazil, 3 Universidade Federal de São Paulo, Sao Paulo, SP, Brazil OBJECTIVES: The aim of this study was to translate and validate a Brazilian version of the "Prolapse -Quality Of Life Questionnaire" (P-QOL) as a specifi c instrument to assess the severity of symptoms and their impact in the quality of life of Brazilian women with genital prolapse. METHODS: Sixty-fi ve patients (45 with symptomatic and 20 with asymptomatic pelvic organ prolapse), were enrolled from the outpatient clinic of the Uroginecology and Vaginal Surgery Section of the Gynecology Department of the Federal University of São Paulo (UNIFESP). At fi rst, we translated the P-QOL
